• Targeted mRNA Nanoparticles Restore BBB After Ischemic Strok

  2026-08-04

  This study demonstrates a lipid nanoparticle platform that delivers IL-10 mRNA to the ischemic brain, promoting microglial polarization toward a reparative phenotype and restoring blood–brain barrier (BBB) integrity after stroke. The approach offers a novel mechanistic route to limit neuroinflammation and improve functional outcomes in preclinical models, with implications for extending therapeutic windows in stroke intervention.

• CD36-Driven Lipid Metabolism Enables Immune Escape in AML

  2026-08-04

  Guo et al. (2024) demonstrate that CD36-mediated uptake of oxidized LDL and palmitate in acute myeloid leukemia (AML) cells activates a non-canonical immune signaling pathway, suppressing T cell proliferation and promoting resistance to hypomethylating therapy. These findings elucidate a metabolic-immune axis in AML and suggest translational strategies targeting CD36 to enhance therapeutic efficacy.

• Comparative In Vitro Activity: Sisomicin, Tobramycin, and Ge

  2026-08-03

  The reference study by Stewart and Bodey provided a rigorous side-by-side assessment of sisomicin’s in vitro activity versus established aminoglycosides, including tobramycin and gentamicin, across diverse clinical isolates. Their findings clarified relative potency, resistance overlap, and the implications for antibiotic selection and resistance monitoring in microbiology research.

• RepSox ALK5 Inhibitor: Driving Efficient iPSC Platelet Yield

  2026-08-03

  RepSox, a potent and selective ALK5 inhibitor from APExBIO, enables high-yield, cost-effective differentiation of platelets from induced pluripotent stem cells (iPSCs), pushing the boundaries of regenerative medicine. This article delivers stepwise workflows, practical troubleshooting, and comparative insights anchored in the latest reference studies.

• Dimetridazole (BA1077): Reliable Solutions for Lab Assays

  2026-08-02

  This article provides an evidence-based exploration of how Dimetridazole (SKU BA1077) addresses key laboratory challenges in cell viability, antimicrobial, and infection model assays. Drawing on recent literature and validated protocols, we evaluate scenario-driven questions from bench scientists and highlight the practical benefits of Dimetridazole for reproducibility, sensitivity, and workflow optimization.

• nor-NOHA (acetate): Arginase Inhibition for Cancer Research

  2026-08-01

  nor-NOHA (acetate) is a potent, reversible arginase inhibitor that modulates L-arginine metabolism, enhancing nitric oxide production. It shows efficacy in suppressing cancer cell proliferation and migration, with validated effects in HepG2 and rat models. This dossier details its mechanisms, benchmarks, and best practices in research workflows.

• Precision Protein Markers: Catalyzing Translational Discover

  2026-07-31

  Translational researchers face mounting challenges in decoding molecular mechanisms of drug resistance and signaling pathways in complex diseases such as lung adenocarcinoma. This thought-leadership article explores how advanced protein analysis tools—especially the APExBIO Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa)—empower rigorous, reproducible workflows for SDS-PAGE and Western blotting. We synthesize recent mechanistic breakthroughs, including the ARID1A-PTEN-Akt axis in osimertinib resistance, and provide actionable guidance for integrating next-generation molecular weight standards into translational pipelines. Distinct from conventional product spotlights, this article builds a mechanistic and strategic bridge for researchers seeking to future-proof their protein analysis.

• Asunaprevir (BMS-650032): Integrative Insights for Precision

  2026-07-31

  Explore how Asunaprevir (BMS-650032) enables precision inhibition of HCV RNA replication and offers unique value for antiviral and host-pathway research. This article delivers advanced assay guidance and cross-disciplinary context for scientists seeking next-generation hepatitis C virus tools.

• CLCC1 Identified as Essential Mediator of Herpesvirus Nuclea

  2026-07-30

  A recent study has revealed CLCC1 as a critical host factor enabling membrane fusion during herpesvirus nuclear egress. This discovery clarifies a key step in herpesvirus replication and exposes new avenues for antiviral research and immunomodulatory intervention.

• NLRP10 Regulates Epidermal Homeostasis in Atopic Dermatitis

  2026-07-30

  The referenced study uncovers the essential function of NLRP10 in maintaining keratinocyte survival and promoting p63-dependent differentiation, directly linking reduced NLRP10 expression to impaired skin barrier integrity in atopic dermatitis. These mechanistic insights highlight NLRP10 as a promising therapeutic target for restoring epidermal homeostasis in AD.

• MK-8745: Potent Aurora A Inhibitor for Cell Cycle & Apoptosi

  2026-07-29

  MK-8745 is a highly selective Aurora A inhibitor with nanomolar potency for interrupting mitosis and inducing apoptosis in cancer models. Its utility is underscored by robust evidence of Aurora A overexpression in high-risk tumors, making it a preferred tool for translational oncology research.

• L. acidophilus and UDCA Modulate Immune Responses in Ulcerat

  2026-07-29

  The study by Deng et al. demonstrates that Lactobacillus acidophilus and its metabolite ursodeoxycholic acid (UDCA) alleviate ulcerative colitis in mice by promoting regulatory T cell differentiation and inhibiting pro-inflammatory macrophage polarization. These findings clarify the immune-modulatory mechanisms of probiotics and microbial metabolites in inflammatory bowel disease models, offering new avenues for targeted microbiome-based therapies.

• CB-839 (Telaglenastat): Optimizing Cancer Metabolism Assays

  2026-07-28

  CB-839 (Telaglenastat), a potent and selective GLS1 inhibitor from APExBIO, enables precise dissection of glutaminolysis in cancer metabolism research. This article details advanced workflows, troubleshooting strategies, and the translational impact of recent epitranscriptomic discoveries—empowering researchers to extract robust, reproducible insights from metabolic vulnerability assays.

• BOP Reagent: Accelerating Next-Gen Peptide & Prodrug Design

  2026-07-28

  Explore how BOP reagent (benzotriazol-1-yloxy-tris(dimethylamino)phosphanium hexafluorophosphate) empowers translational researchers to bridge high-fidelity peptide synthesis and advanced prodrug design, particularly in the context of targeted oral squamous cell carcinoma (OSCC) chemotherapeutics. This thought-leadership article synthesizes mechanistic insights, protocol guidance, and competitive context, linking foundational chemistry to clinical innovation and highlighting APExBIO's leadership in reliable peptide coupling solutions.

• Pam3CSK4 TFA: Advancing TLR1/2 Science in Maternal-Neonatal

  2026-07-27

  This thought-leadership article examines how Pam3CSK4 TFA, a synthetic TLR1/2 agonist, is redefining translational immunology in the context of maternal Group B Streptococcus (GBS) colonization and neonatal risk assessment. Integrating recent cytokine biomarker discoveries, the piece offers mechanistic, experimental, and strategic insights for researchers seeking to leverage TLR1/2 pathway activators for high-impact maternal-fetal health studies. By critically referencing landmark findings and APExBIO’s product advantages, the article maps a forward-looking strategy for translational teams aiming for reproducibility, biomarker clarity, and clinical relevance.

450 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page